ChromaDex (NASDAQ:CDXC) Rating Lowered to Buy at StockNews.com

ChromaDex (NASDAQ:CDXC) was downgraded by research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued on Thursday.

A number of other research firms also recently weighed in on CDXC. LADENBURG THALM/SH SH lifted their target price on ChromaDex from $6.80 to $8.10 and gave the stock a “buy” rating in a research report on Wednesday. Roth Mkm lifted their price target on shares of ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a report on Wednesday, November 6th.

ChromaDex Price Performance

Shares of CDXC stock opened at $7.70 on Thursday. The stock’s 50-day moving average is $5.77 and its two-hundred day moving average is $5.18. ChromaDex has a fifty-two week low of $1.61 and a fifty-two week high of $9.18. The firm has a market cap of $588.15 million, a P/E ratio of 770.77 and a beta of 2.21.

Insider Activity

In other ChromaDex news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $6.19, for a total value of $230,026.59. Following the sale, the director now owns 244,179 shares in the company, valued at $1,511,468.01. This represents a 13.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 9.64% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On ChromaDex

Large investors have recently added to or reduced their stakes in the business. Barclays PLC raised its position in shares of ChromaDex by 322.1% in the third quarter. Barclays PLC now owns 70,072 shares of the company’s stock valued at $256,000 after purchasing an additional 53,472 shares during the period. Sargent Investment Group LLC acquired a new stake in ChromaDex during the fourth quarter worth approximately $263,000. FMR LLC acquired a new stake in ChromaDex during the 3rd quarter worth approximately $55,000. JPMorgan Chase & Co. boosted its stake in ChromaDex by 11.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 331,916 shares of the company’s stock valued at $1,211,000 after purchasing an additional 33,150 shares during the period. Finally, State Street Corp grew its holdings in ChromaDex by 11.3% in the 3rd quarter. State Street Corp now owns 618,028 shares of the company’s stock valued at $2,256,000 after buying an additional 62,692 shares in the last quarter. Institutional investors own 15.41% of the company’s stock.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.